Company Profile
Viking Therapeutics Stock Price, News & Catalysts
- Ticker:
- VKTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.79 USD (-7.79%)
Close
Last updated: November 5, 2026
3.4B USD
Market cap
Why the stock is moving
As of Nov 5, 2026, VKTX closed down 7.79% at $25.79. No new same-company headline was identified in the current news window.
Company overview
Metabolic and Endocrine Drug Developer
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its pipeline is led by obesity programs and also includes candidates for metabolic liver disease and a rare neurological disorder.
VK2735 Obesity Franchise
VK2735 is a dual GLP-1 and GIP receptor agonist being developed in both subcutaneous and oral formulations. Viking is positioning the candidate as a flexible obesity platform that could support induction, maintenance, and less-frequent dosing strategies.
Phase 3 VANQUISH Program
The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 study in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Both trials measure weight change after 78 weeks and include extension studies for longer-term treatment.
Oral SUNRISE Program
The Phase 3 SUNRISE program evaluates oral VK2735 in populations that parallel the VANQUISH studies. The oral formulation is intended to offer a tablet-based alternative within the same dual-agonist franchise.
Maintenance and Amylin Programs
Viking is studying oral, every-other-week subcutaneous, and monthly subcutaneous VK2735 maintenance regimens after an initial induction period. It is also advancing VK3019, a dual amylin and calcitonin receptor agonist, as a separate obesity mechanism.
Additional Metabolic Pipeline
VK2809 is an oral thyroid hormone receptor beta agonist that has completed Phase 2b evaluation in metabolic dysfunction-associated steatohepatitis. VK0214 is being developed for X-linked adrenoleukodystrophy, extending the pipeline beyond obesity and liver disease.
Future catalysts
- Completion of the Phase 1 single-ascending-dose study of VK3019 later in the fourth quarter of 2026.
- Initiation of a four-week multiple-ascending-dose study of VK3019 in the first quarter of 2027.
- Commencement of the VANQUISH extension studies in the first quarter of 2027.
- Completion of the Phase 3 VANQUISH-1 and VANQUISH-2 studies in 2027.
- Results from Part 2 of the VK2735 maintenance-dosing study in 2027.
- Results from the VANQUISH extension studies in 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Viking Therapeutics (VKTX)?
Viking Therapeutics (VKTX) most recently closed at 25.79 USD, a -7.79% move versus the previous session.
What is the market cap of Viking Therapeutics (VKTX)?
Viking Therapeutics currently has a market capitalization of 3.4B USD on BioPharmSignal.
What does Viking Therapeutics do?
Metabolic and Endocrine Drug Developer Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its pipeline is led by obesity programs and also includes candidates for metabolic liver disease and a rare neurological disorder. VK2735 Obesity Franchise VK2735 is a dual GLP-1 and GIP...
On which exchange is VKTX stock listed?
Viking Therapeutics (VKTX) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
VK2735 Obesity Franchise VK2735 is a dual GLP-1 and GIP receptor agonist being developed in both subcutaneous and oral formulations.
Which conditions is Viking Therapeutics targeting with GLP-1?
Viking Therapeutics is associated with metabolic disease, obesity, diabetes based on its company overview and current catalyst commentary.
How does Viking Therapeutics describe recent progress with GLP-1?
Completion of the Phase 1 single-ascending-dose study of VK3019 later in the fourth quarter of 2026. Initiation of a four-week multiple-ascending-dose study of VK3019 in the first quarter of 2027. Commencement of the VANQUISH extension studies in the first quarter of 2027. Completion of the Phase 3 VANQUISH-1 and VANQUISH-2 studies in 2027. Results from...
What is VANQUISH-1?
Phase 3 VANQUISH Program The subcutaneous formulation is being evaluated in the Phase 3 VANQUISH-1 study in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes.